Shanghai Longwood Biopharmaceuticals Co., Ltd.

Sai Yang

Zhe Wang

Zhihong Zeng

Xiaoguang Wang

Guoqin Fan

Cenbin Lu

The present invention relates to a bicyclic nucleocapsid inhibitor and the use of the same as a drug in the treatment of hepatitis B. In particular, disclosed is a compound having a structure shown by the following formula (A1): or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt, a hydrate, or a solvate thereof, that can be used as an HBV inhibitor, wherein the definition of each group is as described in detail in the description. The present invention also relates to a pharmaceutical composition comprising the compound and the use of the same in the treatment of hepatitis B.

Substituted pyrrolizines for the treatment of hepatitis B

Provided is a selective JAK kinase selective inhibitor and a preparation method and the use thereof. In particular, provided is a compound having the structure as shown in chemical formula (I) as a JAK kinase inhibitor or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt, a hydrate or a solvate thereof. 

JAK kinase inhibitor and preparation method and use thereof

Disclosed are an endocyclic thiamidinoamide-arylamide compound and a pharmaceutical composition comprising the compound described above, and the use of the compound or pharmaceutical composition in the treatment of hepatitis B. In particular, disclosed is a compound that can be used as an HBV replication inhibitor and has the structure as shown in chemical formula (L), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof. 

Growing community of inventors

Shanghai, China

Sai Yang